Literature DB >> 2277720

Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia.

Jean Joris1, Ann Costello, Ronald Dubner, Kenneth M Hargreaves.   

Abstract

This study determined whether opiates alter vascular components of inflammation (hyperthermia, edema and plasma extravasation) in addition to the suppression of hyperalgesia. Rats were administered carrageenan into one hind paw and saline into the other hind paw, followed by i.p. injection of morphine (0.2-5.0 mg/kg) or saline at 60 min, and testing at 90 min after hind paw injections. Morphine produced a dose-dependent reduction in carrageenan-induced hyperalgesia (17-53%), hyperthermia (39-53%) and edema (24-36%). Morphine treatment did not alter the temperatures of the contralateral saline-injected paws, indicating that opiate suppression of hyperthermia was not confounded by alterations in systemic body temperature or blood flow. The opiate effects on inflammation were stereospecific since levorphanol (1 mg/kg), but not dextrorphan (1 mg/kg), suppressed carrageenan-evoked hyperalgesia, hyperthermia and edema. Pre-treatment with naltrexone (1.5 mg/kg) blocked the effects of a 5 mg/kg dose of morphine sulfate on hyperalgesia, hyperthermia and edema. In a separate study, i.v. injection of morphine sulfate (2 mg/kg) reduced plasma extravasation by 41% (P less than 0.01). Morphine administration resulted in significantly greater increases in paw withdrawal latencies in the inflamed (38-139%) than the contralateral, saline-treated paws (4-19%). The results indicate that opiates exert a moderate, though significant, reduction in the vascular signs of inflammation in addition to their reduction of hyperalgesia. The mechanisms for this vascular effect involve inhibition of both vasodilation (as indicated by a decrease in hyperthermia) and inhibition of vascular permeability. In addition, opiates exhibit enhanced antinociceptive effects in inflamed paws, even when compared to uninjured paws in the same animal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2277720     DOI: 10.1016/0304-3959(90)90054-H

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  23 in total

1.  The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation.

Authors:  R W Hurley; D L Hammond
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

2.  Spinal and peripheral mechanisms involved in the enhancement of morphine analgesia in acutely inflamed mice.

Authors:  Sara González-Rodríguez; Agustín Hidalgo; Ana Baamonde; Luis Menéndez
Journal:  Cell Mol Neurobiol       Date:  2009-08-05       Impact factor: 5.046

3.  Effects of transgene-mediated endomorphin-2 in inflammatory pain.

Authors:  Shuanglin Hao; Darren Wolfe; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2008-06-24       Impact factor: 3.931

4.  Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.

Authors:  Laura C Sullivan; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2015-01-30       Impact factor: 4.030

5.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

Review 6.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

7.  Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat.

Authors:  P Honoré; J Buritova; J M Besson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

8.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

9.  Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice.

Authors:  Sara González-Rodríguez; Agustín Hidalgo; Ana Baamonde; Luis Menéndez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-26       Impact factor: 3.000

10.  The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation.

Authors:  Dimitris N Xanthos; Naresh Kumar; Elvar Theodorsson; Terence J Coderre
Journal:  Neuropharmacology       Date:  2008-12-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.